Immune checkpoint inhibitors (ICIs) play a significant anti-tumor effect through T cell regulatory pathway, including immunotherapeutic drugs targeting programmed death receptor 1 (PD-1) / programmed death-ligand 1 (PD-L1), such as pembrolizumab, nivolumab, and atezolizumab. This evidence concerns the gene CD274 and neoplasm.